SEARCH

SEARCH BY CITATION

References

  • Abba K, Ramaratnam S & Ranganathan LN (2010) Anthelmintics for people with neurocysticercosis. Cochrane Database Systematic Review, C CD000215.
  • Bern C, Garcia HH, Evans C et al. (1999) Magnitude of the disease burden from neurocysticercosis in a developing country. Clinical Infectious Diseases 29 12031209.
  • Bickerstaff ER, Cloake PCP, Hughes B & Smith WT (1952) The racemose form of cerebral cysticercosis. Brain 75, 116.
  • Bickerstaff ER, Small JM & Woolf AL (1956) Cysticercosis of the posterior fossa. Brain 79, 622634.
  • Bobes RJ, Hernandez M, Marquez C et al. (2006) Subarachnoidal and intraventricular human neurocysticercosis: application of an antigen detection assay for the diagnosis and follow-up. Tropical Medicine & International Health 11, 943950.
  • Cruz ME, Schantz PM, Cruz I et al. (1999) Epilepsy and neurocysticercosis in an Andean community. International Journal of Epidemiology 28, 799803.
  • Del Brutto OH, Santibanez R, Idrovo L et al. (2005) Epilepsy and neurocysticercosis in Atahualpa: a door-to-door survey in rural coastal Ecuador. Epilepsia 46, 583587.
  • Del Brutto OH, Roos KL, Coffey CS & Garcia HH (2006) Meta-analysis: cysticidal drugs for neurocysticercosis: albendazole and praziquantel. Annals of Internal Medicine 145, 4351.
  • Dorny P, Brandt J, Zoli A & Geerts S (2003) Immunodiagnostic tools for human and porcine cysticercosis. Acta Tropica 87, 7986.
  • Dumas JL, Vusy JM & Belin C (1997) Parenchymal neurocysticercosis: follow up and staging by MRI. Neuroradiology 39, 1216.
  • Espinoza B, Ruiz-Palacios G, Tovar A, Sandoval MA, Plancarte A & Flisser A (1986) Characterization by enzyme-linked immunosorbent assay of the humoral immune response in patients with neurocysticercosis and its application in immunodiagnosis. Journal of Clinical Microbiology 24, 536541.
  • Esquivel-Velazquez M, Ostoa-Saloma P, Morales-Montor J, Hernandez-Bello R & Larralde C (2011) Immunodiagnosis of neurocysticercosis: ways to focus on the challenge. Journal of Biomedicine & Biotechnology 2011, 516042.
  • Estanol B, Corona T & Abad P (1986) A prognostic classification of cerebral cysticercosis: therapeutic implications. Journal of Neurology, Neurosurgery and Psychiatry 49, 11311134.
  • Fleury A, Hernández M, Avila M et al. (2007) Detection of HP10 antigen in serum for diagnosis and follow-up of subarachnoidal and intraventricular human neurocysticercosis. Journal of Neurology, Neurosurgery and Psychiatry 78, 970974.
  • Fleury A, Carrillo-Mezo R, Flisser A, Sciutto E & Corona T (2010) Subarachnoid basal neurocysticercosis: a focus on the most severe form of the disease. Expert Review of Anti-Infective Therapy 9, 123133.
  • Garcia HH (2007) Serological diagnosis and follow-up of severe neurocysticercosis using HP10 antigen detection. Nature Clinical Practice Neurology 3, 488489.
  • Garcia HH & Del Brutto OH (2003) Imaging findings in neurocysticercosis. Acta Tropica 87, 7178.
  • Garcia HH, Gilman RH, Catacora M, Verastegui M, Gonzalez AE & Tsang VC (1997) Serologic evolution of neurocysticercosis patients after antiparasitic therapy. Cysticercosis Working Group in Peru. Journal of Infectious Diseases 175, 486489.
  • Garcia HH, Pretell EJ, Gilman RH et al. (2004) A trial of antiparasitic treatment to reduce the rate of seizures due to cerebral cysticercosis. New England Journal of Medicine 350, 249258.
  • Garcia HH, Del Brutto OH, Nash TE, White AC Jr, Tsang VC & Gilman RH (2005) New concepts in the diagnosis and management of neurocysticercosis (Taenia solium). American Journal of Tropical Medicine and Hygiene 72, 39.
  • Garcia HH, Dorny P, Castillo Y et al. (2010) Circulating antigen levels follow post-treatment evolution of subarachnoid neurocysticercosis. Neuroparasitology 1, 13.
  • Garcia HH, Gonzalez AE & Gilman RH (2011) Cysticercosis of the central nervous system: how should it be managed? Current Opinion in Infectious Diseases 24, 423427.
  • Gonzalez AE, Gilman R, Garcia HH et al. (1994) Use of sentinel pigs to monitor environmental Taenia solium contamination. The Cysticercosis Working Group in Peru (CWG). American Journal of Tropical Medicine and Hygiene 51, 847850.
  • Gonzalez AE, Garcia HH, Gilman RH, Tsang VCW & the Cysticercosis Working Group in Peru. (2003) Control of Taenia solium. Acta Tropica 87, 103109.
  • Medina MT, Duron RM, Martinez L et al. (2005) Prevalence, incidence, and etiology of epilepsies in rural Honduras: the Salama Study. Epilepsia 46, 124131.
  • Montano SM, Villaran MV, Ylquimiche L et al. (2005) Neurocysticercosis: association between seizures, serology, and brain CT in rural Peru. Neurology 65, 229233.
  • Nash TE & Garcia HH (2011) Diagnosis and treatment of neurocysticercosis. Nature Reviews. Neurology 7, 584594.
  • Ndimubanzi PC, Carabin H, Budke CM et al. (2010) A systematic review of the frequency of neurocyticercosis with a focus on people with epilepsy. PLoS Neglected Tropical Diseases 4, e870.
  • Rodriguez S, Dorny P, Tsang VC et al. (2011) Detection of Taenia solium antigens and anti-T. solium antibodies in paired serum and cerebrospinal fluid samples from patients with intraparenchymal or extraparenchymal neurocysticercosis. Journal of Infectious Diseases 199, 13451352.
  • Rosas N, Sotelo J & Nieto D (1986) ELISA in the diagnosis of neurocysticercosis. Archives of Neurology 43, 353356.
  • Tsang V & Wilson M (1995) Taenia solium cysticercosis, an under-recognized but serious public health problem. Parasitol Today 12, 4126.
  • Tsang VC, Brand JA & Boyer AE (1989) An enzyme-linked immunoelectrotransfer blot assay and glycoprotein antigens for diagnosing human cysticercosis (Taenia solium). Journal of Infectious Diseases 159, 5059.
  • Zamora H, Castillo Y, Garcia HH et al. (2005) Drop in antigen levels following successful treatment of subarachnoid neurocysticercosis. American Journal of Tropical Medicine and Hygiene 73, S41.